Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy (Q38793772)

6 September 2017

title

Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy (English)

1 reference

6 September 2017

1 reference

1 reference

3

0 references

Nora Hagelberg

series ordinal

2

object named as

Nora M Hagelberg

1 reference

6 September 2017

Marko A Peltoniemi

1

1 reference

6 September 2017

Teijo I Saari

series ordinal

4

1 reference

6 September 2017

publication date

30 March 2016

1 reference

Clinical Pharmacokinetics

6 September 2017

published in

1 reference

6 September 2017

volume

55

1 reference

6 September 2017

issue

9

1 reference

6 September 2017

page(s)

1059-1077

1 reference

PHARMACOLOGIC EFFECTS OF CI-581, A NEW DISSOCIATIVE ANESTHETIC, IN MAN.

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine: a controversial drug for neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Pharmacokinetics and analgesic effects of i.m. and oral ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Rifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Effects of norketamine enantiomers in rodent models of persistent pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

A systematic review of intravenous ketamine for postoperative analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Vom Razemat zum Eutomer: (S)-Ketamin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Effect of racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation of pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine as an adjuvant to opioids for cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Peri-operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review (Cochrane review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine for the treatment of refractory status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

The binding of ketamine to plasma proteins: emphasis on human plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

S(+)-ketamine effect on experimental pain and cardiac output: a population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Comparative pharmacology of the ketamine isomers. Studies in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Pharmacokinetics of S(+) ketamine derived from target controlled infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

St John's wort greatly decreases the plasma concentrations of oral S-ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

S-ketamine concentrations are greatly increased by grapefruit juice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Biotransformation of ketamine, (Z)-6-hydroxyketamine, and (E)-6-hydroxyketamine by rat, rabbit, and human liver microsomal preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Metabolism of ketamine stereoisomers by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine disposition in children presenting for procedural sedation and analgesia in a children's emergency department.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Investigating the pharmacodynamics of ketamine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Modeling the norketamine metabolite in children and the implications for analgesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Dosing ketamine for pediatric procedural sedation in the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Population pharmacokinetics of ketamine in children with heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Predictive performance of the Domino, Hijazi, and Clements models during low-dose target-controlled ketamine infusions in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Reporting a population pharmacokinetic-pharmacodynamic study: a journal's perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Effects of ketamine and three other anaesthetics on spinal reflexes and inhibitions in the cat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

The role of nitric oxide in orofacial pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Antinociceptive interactions of ketamine with morphine or methadone in mononeuropathic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Analgesic effect in humans of subanaesthetic isoflurane concentrations evaluated by experimentally induced pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Wind-up and the NMDA receptor complex from a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

The effect of naloxone on ketamine-induced effects on hyperalgesia and ketamine-induced side effects in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Dexmedetomidine premedication attenuates ketamine-induced cardiostimulatory effects and postanesthetic delirium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Subanesthetic ketamine does not affect 11C-flumazenil binding in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Intravenous anesthetics differentially modulate ligand-gated ion channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

[3H]MK-801 binding sites in post-mortem human frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Physostigmine in recovery from anaesthesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

A randomized evaluation of the reversal of ketamine by physostigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Blockade of voltage-operated neuronal and skeletal muscle sodium channels by S(+)- and R(-)-ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Pharmacokinetics and analgesic effect of ketamine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

The clinical use of S-(+)-ketamine--a determination of its place

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine is a safe, effective, and appropriate technique for emergency department paediatric procedural sedation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

No inhibition of gastro-intestinal propulsion after propofol- or propofol/ketamine-N2O/O2 anaesthesia. A comparison of gastro-caecal transit after isoflurane anaesthesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Morphine and ketamine is superior to morphine alone for out-of-hospital trauma analgesia: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

The first 500: initial experience with widespread use of low-dose ketamine for acute pain management in the ED.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

The use of intravenous infusion or single dose of low-dose ketamine for postoperative analgesia: a review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine and postoperative pain--a quantitative systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Non-opioid IV adjuvants in the perioperative period: pharmacological and clinical aspects of ketamine and gabapentinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Effect of i.v. ketamine in combination with epidural bupivacaine or epidural morphine on postoperative pain and wound tenderness after renal surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Lack of pre-emptive analgesic effect of (R)-ketamine in laparoscopic cholecystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Perioperative ketamine for acute postoperative pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Comparative effects of ketamine on Bispectral Index and spectral entropy of the electroencephalogram under sevoflurane anaesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Comparison of S-(+)-ketamine- with sufentanil-based anaesthesia for elective coronary artery bypass graft surgery: effect on troponin T levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Effects of ketamine on the contractility of failing and nonfailing human heart muscles in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

S(+)-ketamine as an analgesic adjunct reduces opioid consumption after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Special Articles: 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

NMDA Antagonist Neurotoxicity: Mechanism and Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Repeated administration of ketamine may lead to neuronal degeneration in the developing rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine potentiates cerebrocortical damage induced by the common anaesthetic agent nitrous oxide in adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Dual effects of ketamine: neurotoxicity versus neuroprotection in anesthesia for the developing brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine enhances human neural stem cell proliferation and induces neuronal apoptosis via reactive oxygen species-mediated mitochondrial pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Repeated exposure to anesthetic ketamine can negatively impact neurodevelopment in infants: a prospective preliminary clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Brain protection by anesthetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Impact of anaesthetics and surgery on neurodevelopment: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Neuroprotection of S(+) ketamine isomer in global forebrain ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Neuroprotection by ketamine: a review of the experimental and clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

S-ketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Revising a dogma: ketamine for patients with neurological injury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

The ketamine effect on ICP in traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Persistent postsurgical pain: risk factors and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

A systematic review and meta-analysis of ketamine for the prevention of persistent post-surgical pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

A systematic review of therapeutic interventions to reduce acute and chronic post-surgical pain after amputation, thoracotomy or mastectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Perioperative epidural or intravenous ketamine does not improve the effectiveness of thoracic epidural analgesia for acute and chronic pain after thoracotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Chronic postthoracotomy pain and perioperative ketamine infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine for chronic non-cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine for chronic pain: risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Influence of ketamine and morphine on descending pain modulation in chronic pain patients: a randomized placebo-controlled cross-over proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Effect of ketamine on endogenous pain modulation in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Reduction of allodynia in patients with complex regional pain syndrome: A double-blind placebo-controlled trial of topical ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine for chronic noncancer pain: concerns regarding toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

An evidence based systematic review of remifentanil associated opioid-induced hyperalgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Antidepressant mechanism of ketamine: perspective from preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Repeated S-ketamine infusions in therapy resistant depression: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

The absolute bioavailability of racemic ketamine from a novel sublingual formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

The prevalence and natural history of urinary symptoms among recreational ketamine users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Possible pathophysiology of ketamine-related cystitis and associated treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Ketamine: an update on its abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

Adjunctive atropine is unnecessary during ketamine sedation in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0383-6

S(+)-ketamine, but not R(-)-ketamine, reduces postischemic adherence of neutrophils in the coronary system of isolated guinea pig hearts

21 January 2018

1 reference

12 December 2020

Interaction of Ketamine and Halothane in Rats

1 reference

12 December 2020

Ketamine attenuates neutrophil activation after cardiopulmonary bypass

1 reference

12 December 2020

Pharmacology of ketamine isomers in surgical patients.

1 reference

12 December 2020

Ketamine attenuates the interleukin-6 response after cardiopulmonary bypass

1 reference

12 December 2020

Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro.

1 reference

12 December 2020

The neurotoxicity of drugs given intrathecally (spinal)

1 reference

12 December 2020

Morphine tolerance decreases the analgesic effects of ketamine in mice

1 reference

12 December 2020

Taming the ketamine tiger. 1965.

1 reference

12 December 2020

Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes.

1 reference

12 December 2020

Physostigmine antagonizes ketamine.

1 reference

12 December 2020

Testing computer-controlled infusion pumps by simulation

1 reference

12 December 2020

Ketamine: teaching an old drug new tricks

1 reference

12 December 2020

Potential strategies for preventing chronic postoperative pain: a practical approach: Continuing Professional Development

1 reference

12 December 2020

The analgesic effect of combined treatment with intranasal S-ketamine and intranasal midazolam compared with morphine patient-controlled analgesia in spinal surgery patients: a pilot study

1 reference

12 December 2020

Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors

1 reference

12 December 2020

10.1007/S40262-016-0383-6

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1014054368

0 references

1 reference